Table 2. Laboratory features of Mycobacterium microti isolates from Scotland*†.

Source	Specimen	Direct AFB	Growth on primary isolation				Drug susceptibility	Genotype
			Solid culture			Liquid culture
			IUT	PYR		MB/MGIT
Human 1	Sputum	Positive	–	+		–	Failed to grow in liquid cultures	Llama type SIT641 (spacers 4–7, 23,24, 37, and 38)
Human 2	Sputum	Positive (many)	–	+		–	Failed to grow in liquid cultures	Llama type SIT641
Human 3	Sputum	Positive (many)	–	–		+	Susceptible to R, I, E; resistant to P	Llama type SIT641
Human 4	Sputum	Positive (few)	+	+		–	Failed to grow in liquid culture	Llama type (spacers 4–7 and 23,24 only)
Cat 1	Tissue/lymph node	Negative	–	+		–	Failed to grow in liquid cultures	Llama type SIT641
Badger	Tissue/lung	Strongly positive	+	+		±	Inadequate growth	Vole type SIT 539 (spacers 37 and 38)
Cat 2	Tissue/lymph node	Negative	–	+		–	Susceptible to R,I,E,P (grew on liquid subculture)	Vole type SIT539
Llama	Tissue/lung	Positive	+	+		–	Failed to grow in liquid culture	Llama type SIT641
Ferret	Tissue	Positive	±	±		±	Susceptible to R,I,E,P	Not tested

*AFB, acid-fast bacilli; IUT, International Union Against Tuberculosis formulation of solid egg medium; PYR, IUT medium with pyruvate supplementation; MB, MBBact, Biomerieux, Basingstoke, United Kingdom; MGIT, Mycobacteria Growth Indicator Tube, Becton Dickinson; R,I,E,P, rifampin, isoniazid, ethambutol, pyrazinamide; SIT, Spoligo-International-Type.
†SIT numbers: designations in International spoligotyping database (Spol DB4) (14).